BioCentury
ARTICLE | Company News

Altachem deal

March 25, 2002 8:00 AM UTC

AAF purchased from an undisclosed party exclusive rights to an immunomodulator for 400,000 AAF shares valued at C$920,000 (US$580,980) based on AAF’s Friday close at C$2.30. AAF plans to use the precl...